new biotech drug for diabetic foot ulcers

February 1999

You'll see a new biotech drug for diabetic foot ulcers...called Regranex (becaplermin gel).

It contains a platelet-derived growth factor to stimulate the growth of new tissue...resulting in a modest increase in healing.

This is important. Diabetic foot ulcers are extremely hard to treat...and can lead to serious infections and amputation.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Ophthalmology Azopt, a new eye drop for glaucoma
The U.S. will now allow drug reps to give out information about UNAPPROVED uses of their prescription drugs
Infectious Diseases Trovan (trovafloxacin), a very broad-spectrum quinolone
Infectious Diseases new drug for HIV, Ziagen (abacavir)
Diabetes mix Humalog (insulin lispro) with long-acting insulins
Diabetes new biotech drug for diabetic foot ulcers
Diabetes Glyset (miglitol) for type 2 diabetes
Women's Health New Canadian guidelines are now out for menopausal symptoms
Vaccines Varivax, the first chickenpox vaccine
Vaccines Lymerix, the first vaccine to prevent Lyme disease
Respiratory & Allergy new guidelines for treating chronic obstructive pulmonary disease (COPD)
fenugreek to lower blood sugar
Herp-Eeze, a new supplement for herpes
Gastroenterology new guidelines for treating H. pylori
minocycline is useful for mild to moderate scleroderma
Multiple Sclerosis earlier treatment for patients with multiple sclerosis (MS)
Celebrex (celecoxib), the first COX-2 selective NSAID to hit the market
Practice chart of new drugs approved by the FDA and HPB in 1998